Ultragenyx Pharmaceutical (RARE) vs Replimune Group (REPL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Replimune Group (REPL) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, gaining 189.8% versus a loss of 51.1%. Over five years, REPL leads with a -55.5% price change compared with -80.7% for RARE. Ultragenyx Pharmaceutical is the larger company by market cap ($1.53 billion vs $1.26 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RARE | REPL |
|---|---|---|
| Share price | $15.48 | $13.42 |
| Market cap | $1.53B | $1.26B |
| 1-day change | +1.24% | +2.91% |
| YTD return | -32.70% | +38.07% |
| 1-year return | -51.11% | +189.85% |
| 5-year return | -80.65% | -55.49% |
| Forward P/E | 22.87 | — |
| EPS (TTM) | $-5.82 | $-3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $673.00M | — |
| Revenue growth (YoY) | +20.18% | — |
| Net income (latest FY) | $-575.00M | $-313.94M |
| Operating margin | -79.49% | — |
| Net margin | -85.44% | — |
| 52-week high | $39.89 | $16.33 |
| 52-week low | $12.73 | $1.50 |
| Distance from 52-week high | -61.19% | -17.82% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +73.06% | +45.31% |
| Average volume | 3.89M | 4.15M |
| Shares outstanding | 98.59M | 94.22M |
| Employees | 1,371 | 465 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- REPL has outperformed RARE by 241.0 percentage points over the past year.
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees
About Replimune Group
REPL stock →Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 465 employees
RARE vs REPL FAQ
Which is bigger, Ultragenyx Pharmaceutical or Replimune Group?
Ultragenyx Pharmaceutical (RARE) is larger, with a market capitalization of $1.53B compared with $1.26B for Replimune Group (REPL).
Which stock has performed better over the past year, RARE or REPL?
REPL returned +189.85% over the past 12 months, compared with -51.11% for RARE (price return, excluding dividends). Past performance does not predict future results.
Are Ultragenyx Pharmaceutical and Replimune Group in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Ultragenyx Pharmaceutical and Biotechnology: Biological Products (No Diagnostic Substances) for Replimune Group.